Hybrid Satellite Symposium at the 49th Annual Meeting of the EBMT
Sunday, 23 April 2023
Registration and Lunch
12:00 – 12:30
Panel Discussions + Experienced Patient with CMV
12:30 – 14:00
Paris Congress Centre
Hall 141
Le Palais des Congres de Paris
2 Pl. de la Prte Maillot, 75017
Paris, France
Also Available to Virtual Attendees via Online Simulcast
You must be registered for the 49th Annual Meeting of the EBMT to attend this symposium
FACULTY
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ (Chair)
Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, United States
Rafael F. Duarte, MD, PhD, FRCP (Lon)
Head, Department of Hematology and Transplantation Programme
Hospital Universitario Puerta de Hierro Majadahonda
Profesor Asociado de Hematología
Universidad Autónoma de Madrid
Madrid, Spain
Prof. Sophie Alain, MD
Professor, Virology
Limoges University Hospital
Research Leader, RESINFIT Inserm Team
Limoges University
Limoges, France
In this symposium, an expert panel will discuss cytomegalovirus (CMV) treatment guidelines and benefits and toxicities of traditional CMV therapies in hematopoietic cell transplant (HCT) patients. Panelists will address special challenges associated with refractory or drug-resistant CMV in HCT and present a new treatment option. An experienced patient with CMV will share impactful insights to help provide better care for HCT patients with CMV.
PROGRAM AGENDA
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Rafael F. Duarte, MD, PhD, FRCP (Lon)
Prof. Sophie Alain, MD
All Faculty
TARGET AUDIENCE
Hematopoietic cell transplant (HCT) and hematology/oncology clinicians who manage CMV infection and disease in HCT patients.
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Select cytomegalovirus (CMV) treatment plans in hematopoietic cell transplantation (HCT) patients using evidence-based therapeutic approaches
- Identify critical limitations to conventional CMV therapies that often result in suboptimal outcomes
- Apply best practices for monitoring and treating HCT patients with resistant or refractory CMV
PROVIDER STATEMENT
This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.
SUPPORTER STATEMENT
Supported by an educational grant from Takeda.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
FEE INFORMATION
There is no fee for this educational activity.
FOLLOW RMEI
Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.